[ sulge aken ]
| Elulookirjeldus (CV) | ||
| 1. | Eesnimi | Vallo |
| 2. | Perekonnanimi | Tillmann |
| 3. | Töökoht | Tartü Ülikooli lastekliinik |
| 4. | Ametikoht | kliiniku juhataja, professor |
| 5. | Sünniaeg | 28.08.1963 (päev.kuu.aasta) |
| 6. | Haridus | 2000 - Doctor of Medicine (M.D.), University of Manchester, Suurbritannia 1989 - Internatuuri diplom pediaatrias, Tartu Ülikooli Kliiniline Lastehaigla 1988 - Diplom (cum laude), arstiteaduskond, Tartu Ülikool |
| 7. | Teenistuskäik | 2003 - Korraline professor, TÜ lastekliiniku juhataja 2003 - SA TÜ Kliinikumi lastekliiniku juhataja 2001 - 2003 Vanemteadur, Tartu Ülikooli lastekliinik 2001 - 2003 Arst-õppejõud, SA TÜK lastekliinik 1999 - 2001 Senior Clinical Research Fellow in Oncology, Sheffield Children’s Hospital, Sheffield, Suurbritannia 1996-1999 Clinical Research Fellow in Paeditric Endocrinology, Royal Manchester Children’s Hospital, Manchester, Suurbritannia 1994-1996 ESPE Clinical Fellow in Endocrinology and Diabetes, Royal Manchester Children’s Hospital, Manchester, Suurbritannia 1993-1994 Doktorant, TÜ arstiteaduskond, pediaatria õppetool 1992-1993 Pediaatria osakonna juhataja, Keila Haigla 1989-1992 Arst-pediaater, Keila Haigla 1988-1989 Intern, Tartu Ülikooli lastehaigla |
| 8. | Teaduskraad | Doctor of Medicine (M.D.) |
| 9. | Teaduskraadi välja andnud asutus, aasta |
University of Manchester, Suurbritannia, 2000 |
| 10. | Tunnustused | |
| 11. | Teadusorganisatsiooniline ja –administratiivne tegevus |
European Agency for the Evaluation of Medicinal Products (EMEA)juures asuva Committee for Orphan Medicinal Products (COMP) - liige The Endocrine Society - liige The Baltic Endocrine Society - juhatuse liige The European Society of Paediatric Endocrinology - liige Eesti Lastearstide Selts -liige Eesti Endokrinoloogide Selts - juhatuse liige |
| 12. | Juhendamisel kaitstud väitekirjad |
|
| 13. | Teadustöö põhisuunad | 1. Kasvuhormooni (KH) puudulikkuse diagnostika lastel: erinevad diagnoosimismeetodid, nende sensitiivsus, sptsiifilisus ja efektiivsus, sõltuvus KH puudulikkuse etioloogiast. 2. Kasvuhormoonravist tingitud hormonaalsed ja biokeemilised muutused veres (kasvufaktorid, luuainevahetuse markerid), nende muutuste seos lühiajalise kasvuga. Ravi efektiivsuse ja järjepidevuse hindamine. 3. Laste lühiajalise kasvamise metodoloogilised, biokeemilised ja kliinilised aspektid. 4.Laste ägeda lümfoblastilise leukeemia ravi kaugmõjud, eeskätt luutihedusele ja keha kompositsioonile. Ravi mõju õppimisvõimele. Füüsilise aktiivsuse mõju luutihedusele. 5.Vere leptiini sisalduse sõltuvus lapse vanusest, soost ja puberteedi astmest. Hilinenud puberteedi seos suhtelise leptiini defitsiidiga. 6. Adrenogenitaalne sündroom, selle levimus Eestis, fenotüüp-genotüüp korrelatsioon, haiguse ja selle ravi mõju kasvamisele, vererõhule ja luutihedusele ja -ainevahetusele. |
| 14. | Jooksvad grandid | 2004-2007 GARLA 5835 "Kaasasündinud adrenogenitaalset sündroomi levik Eestis: 21-hüdroksülaasi puudulikkuse genotüübi ja kliinilise pildi vaheline seos, haiguse mõju vererõhule ja lühiajalisele kasvamisele" - grandihoidja 2005-2011 TARLA 2695 "Lapse arengut ja krooniliste haiguste etiopatogeneesi määravad varajased tegurid ja sellest tulenevad uued võimalused nende mõjutamiseks ja raviks" - grandihoidja |
| 15. | Teaduspublikatsioonid |
Oiglane-Shlik E, Rein R, Tillmann V, Talvik T, Ounap K. A female with Angelman syndrome and unusual limb deformities. Pediatr Neurol. 2005;33:66-69 Tillmann V, Davies HA, Bishop NJ. Bone Disease in Pediatric Malignancies. In Jasmin C et al. (ed). Textbook of Bone Metastases. John Wiley & Sons Ltd, 2005, 459-467 Arikoski P, Silverwood B, Tillmann V, Bishop NJ. Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy. Bone. 2004;34:539-46 Zaman N, Hall CM, Gill MS, Jones J, Tillmann V, Westwood M, Whatmore AJ, Clayton PE. Leptin measurement in urine in children and its relationship to other growth peptides in serum and urine. Clin Endocrinol 2003;58:78-85 Tillmann V, Foster PJ, Gill MS, Price DA, Clayton PE. Short-term growth pattern in children with growth disorders. Ann Human Biol, 2002; 29: 89-109 Tillmann V, Molkenboer ASE, Eiser C, Bishop NJ, Davies HA. Male sex and low physical activity are associated with reduced bone mineral density in survivors of childhood leukaemia. J Bone Miner Res 2002;17:1073-1080 Trueman JA, Tillmann V, Cusick CF, Foster P, Patel L, Hall CM, Price DA, Clayton PE. Suppression of puberty with long-acting goserelin (Zoladex-LA): effect on gonadotrophin response to GnRH in the first treatment cycle. Clin Endocrinol 2002; 57:223-230 Eiser K, Tillmann V. Learning difficulties in children treated for acute lymphoblastic leukaemia. Paediatric Rehabilitation 2001; 4: 105-118 Gill MS, Tillmann V, Veldhuis JD, Clayton PE. Patterns of GH Output and Their Synchrony with Short-Term Height Increments Influence Stature and Growth Performance in Normal Children. J Clin Endocrinol Metab 2001;86:5860-3 Tillmann V, Clayton PE. Diurnal variation in height and the reliability of height measurements using stretched and unstretched techniques in the evaluation of short-term growth. Ann Human Biol, 2001; 28;195-206 Tillmann V, Gill MS, Thalange NK, Birkinshaw G, Price DA, Fraser WD, Clayton PE. Short-term changes in growth and urinary growth hormone, insulin-like growth factor-I and markers of bone turnover excretion in healthy prepubertal children. Growth Horm IGF Res 2000: 10: 28-36 Tillmann V, Patel L, Gill MS, Whatmore AJ, Price DA, Kibirige MS, Wales JK, Clayton PE. Monitoring serum insulin-like growth factor-I (IGF-I), IGF binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and leptin during growth hormone treatment for disordered growth. Clin Endocrinol 2000; 53: 329-336 Tillmann V, Tang VWM, Price DA, Hughes DG, Wright NB, Clayton PE Magnetic resonance imaging of the hypothalamic-pituitary axis in the diagnosis of growth hormone deficiency. J Paediatr Endrocrinol 2000;13: 1577-83 Gill MS, Hall CM, Tillmann V, Clayton PE. Constitutional delay in growth and puberty is associated with hypoleptinaemia. Clin Endocrinol 1999, 50:721-726 Gill MS, Thalange NKS, Tillmann V, Foster PJ, Price DA, Diggle PJ, Clayton PE. Regular fluctuations in growth hormone (GH) release determine normal human growth. Growth Horm IGF Res 1999; 9: 114-122 Hall CM, Gill MS, Foster PJ, Pennells L, Tillmann V, Price DA, Clayton PE. Relationship between serum and urinary insulin-like growth factor-I through childhood and adolescence: their use in the assessment of disordered growth. Clin Endocrinol 1999; 50: 611-618 Clayton PE, Tillmann V. Advances in endocrinology. Arch Dis Child 1998;78:278-84 Tillmann V, Shalet SM, Price DA, Wales JKW, Pennells L, Soden J, Gill MS, Whatmore AJ, Clayton PE. Serum insulin-like growth factor-I, IGF binding protein-3 and IGFBP-3 protease activity after cranial irradiation. Horm Res 1998; 50: 71-77 Tillmann V, Thalange NK, Foster PJ, Gill MS, Price DA, Clayton PE. The relationship between stature, growth and short-term changes in height and weight in normal prepubertal children. Pediatr Res 1998; 44:882-886 Clayton PE, Gill MS, Hall CM, Tillmann V, Whatmore AJ, Price DA. Serum leptin through childhood and adolescence. Clinical Endocrinology 1997; 46:727-733 Gill MS, Whatmore AJ, Tillman V, White A, Addison GM, Price DA, Clayton PE. Urinary IGF and IGF binding protein-3 in children with disordered growth. Clinical Endocrinology 1997; 46:483-492 Tillmann V, Buckler JMH, Kibirige MS, Price DA, Shalet SM, Wales JKH, Addison MG, Gill MS, Whatmore AJ, Clayton PE. Biochemical tests in the diagnosis of childhood growth hormone deficiency. J Clin Endocrinol Metab 1997;82:531-535 Tillmann V, Adojaan B, Shor R, Price DA, Tuvemo T. Physical development in Estonian children with type I diabetes. Diabetic Medicine 1996; 13: 97-101 Tillmann V, Price DA, Bucknall JL, Clayton PE. Experience within the Manchester Growth Clinic of growth hormone treatment of girls with Turner syndrome. In Albertsson-Wikland K, Ranke M (ed) Turner Syndrome in a Life-Span Perspective (proceedings of the international meeting). Elsevier Science B.V. 1995, 149-154 |
viimati muudetud: 06.10.2005
| Curriculum Vitae (CV) | ||
| 1. | First Name | Vallo |
| 2. | Surname | Tillmann |
| 3. | Institution | Department of Paediatrics, University of Tartu |
| 4. | Position | Professor of Paediatrics, Chairman |
| 5. | Date of birth | 28.08.1963 (day.month.year) |
| 6. | Education | 2000 - Doctor of Medicine( M.D.), University of Manchester, UK 1989 - Diploma in Paediatrics, Tartu University Children's Hospital 1988 - Diploma in medicine (Medical doctor), University of Tartu |
| 7. | Research and professional experience |
2003 - Professor of Paeditrics, Department of Paeditrics, University of Tartu 2003 - Chairman, Tartu University Children's Hospital 2001 - 2003 Consuldant in Paeditric Endocrinology and Senior Research Fellow, Tartu University Children's Hospital 1999 - 2001 Senior Clinical Research Fellow in Oncology, Sheffield Children’s Hospital, Sheffield, UK 1996-1999 Clinical Research Fellow in Paeditric Endocrinology, Royal Manchester Children’s Hospital, Manchester, UK 1994-1996 ESPE Clinical Fellow in Endocrinology and Diabetes, Royal Manchester Children’s Hospital, Manchester, UK 1993-1994 PhD student, University of Tartu 1992-1993 Head of the paeditric department, Keila Hospital 1989-1992 Paediatrician, Keila Haigla 1988-1989 Intern, Tartu University Children's Hospital |
| 8. | Academic degree | Doctor of Medicine (M.D.) |
| 9. | Dates and sites of earning the degrees |
University of Manchester, UK, 2000 |
| 10. | Honours/awards | |
| 11. | Research-administrative experience |
European Agency for the Evaluation of Medicinal Products (EMEA)Committee for Orphan Medicinal Products (COMP) - member The Endocrine Society - member The Baltic Endocrine Society - member of board The European Society of Paediatric Endocrinology - member The Estonian Society of Paediatrics - member The Estonian Endocrine Society - member of board |
| 12. | Supervised dissertations | |
| 13. | Current research program | 1. Diagnosis of childhood growth hormone (GH) deficiency. Sensitivity, specificity and efficasy of different diagnostic methods. How does the etiology determine the choice of diagnostic methods in GH deficiency. 2.Biochemical and hormonal changes during GH treatment. Relationship between short term changes in growth and biochemical markers (growth factors, bonemarkers). Efficasy and complience of GH treatment. 3. Short-term changes in height and weight in prepubertal children: methodological, clinical and biochemical aspects of short-term growth. 4.Late effects of treatment for acute lümphoblastic leukaemia (ALL) , particularly on bone health and body composition. The impact of physiacl activity on bone health and body composition. Learning difficulties in ALL. 5. Serum leptin during puberty. The role of leptin in delayed puberty. 6. Congenital adrenal hyperplasia in Estonia, the phenotype-genotype correlation, the impact on growth, blood pressure on bone mineral density. |
| 14. | Current grant funding | 2004-2007 GARLA 5835 "Congenital adrenal hyperplasia due to 21-hydroxylase deficiency in Estonia: prevalence, relevance of genotype for clinical picture with particular interest on blood pressure and short-term growth" - principal investigator 2005-2011 TARLA 2695 "Early riskfactors that influence child’s development and pathogenesis of chronic disorders in children: further opportunities for their improvement and treatment" - principal investigator. |
| 15. | List of most important publications |
Oiglane-Shlik E, Rein R, Tillmann V, Talvik T, Ounap K. A female with Angelman syndrome and unusual limb deformities. Pediatr Neurol. 2005;33:66-69 Tillmann V, Davies HA, Bishop NJ. Bone Disease in Pediatric Malignancies. In Jasmin C et al. (ed). Textbook of Bone Metastases. John Wiley & Sons Ltd, 2005, 459-467 Arikoski P, Silverwood B, Tillmann V, Bishop NJ. Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy. Bone. 2004;34:539-46 Zaman N, Hall CM, Gill MS, Jones J, Tillmann V, Westwood M, Whatmore AJ, Clayton PE. Leptin measurement in urine in children and its relationship to other growth peptides in serum and urine. Clin Endocrinol 2003;58:78-85 Tillmann V, Foster PJ, Gill MS, Price DA, Clayton PE. Short-term growth pattern in children with growth disorders. Ann Human Biol, 2002; 29: 89-109 Tillmann V, Molkenboer ASE, Eiser C, Bishop NJ, Davies HA. Male sex and low physical activity are associated with reduced bone mineral density in survivors of childhood leukaemia. J Bone Miner Res 2002;17:1073-1080 Trueman JA, Tillmann V, Cusick CF, Foster P, Patel L, Hall CM, Price DA, Clayton PE. Suppression of puberty with long-acting goserelin (Zoladex-LA): effect on gonadotrophin response to GnRH in the first treatment cycle. Clin Endocrinol 2002; 57:223-230 Eiser K, Tillmann V. Learning difficulties in children treated for acute lymphoblastic leukaemia. Paediatric Rehabilitation 2001; 4: 105-118 Gill MS, Tillmann V, Veldhuis JD, Clayton PE. Patterns of GH Output and Their Synchrony with Short-Term Height Increments Influence Stature and Growth Performance in Normal Children. J Clin Endocrinol Metab 2001;86:5860-3 Tillmann V, Clayton PE. Diurnal variation in height and the reliability of height measurements using stretched and unstretched techniques in the evaluation of short-term growth. Ann Human Biol, 2001; 28;195-206 Tillmann V, Gill MS, Thalange NK, Birkinshaw G, Price DA, Fraser WD, Clayton PE. Short-term changes in growth and urinary growth hormone, insulin-like growth factor-I and markers of bone turnover excretion in healthy prepubertal children. Growth Horm IGF Res 2000: 10: 28-36 Tillmann V, Patel L, Gill MS, Whatmore AJ, Price DA, Kibirige MS, Wales JK, Clayton PE. Monitoring serum insulin-like growth factor-I (IGF-I), IGF binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and leptin during growth hormone treatment for disordered growth. Clin Endocrinol 2000; 53: 329-336 Tillmann V, Tang VWM, Price DA, Hughes DG, Wright NB, Clayton PE Magnetic resonance imaging of the hypothalamic-pituitary axis in the diagnosis of growth hormone deficiency. J Paediatr Endrocrinol 2000;13: 1577-83 Gill MS, Hall CM, Tillmann V, Clayton PE. Constitutional delay in growth and puberty is associated with hypoleptinaemia. Clin Endocrinol 1999, 50:721-726 Gill MS, Thalange NKS, Tillmann V, Foster PJ, Price DA, Diggle PJ, Clayton PE. Regular fluctuations in growth hormone (GH) release determine normal human growth. Growth Horm IGF Res 1999; 9: 114-122 Hall CM, Gill MS, Foster PJ, Pennells L, Tillmann V, Price DA, Clayton PE. Relationship between serum and urinary insulin-like growth factor-I through childhood and adolescence: their use in the assessment of disordered growth. Clin Endocrinol 1999; 50: 611-618 Clayton PE, Tillmann V. Advances in endocrinology. Arch Dis Child 1998;78:278-84 Tillmann V, Shalet SM, Price DA, Wales JKW, Pennells L, Soden J, Gill MS, Whatmore AJ, Clayton PE. Serum insulin-like growth factor-I, IGF binding protein-3 and IGFBP-3 protease activity after cranial irradiation. Horm Res 1998; 50: 71-77 Tillmann V, Thalange NK, Foster PJ, Gill MS, Price DA, Clayton PE. The relationship between stature, growth and short-term changes in height and weight in normal prepubertal children. Pediatr Res 1998; 44:882-886 Clayton PE, Gill MS, Hall CM, Tillmann V, Whatmore AJ, Price DA. Serum leptin through childhood and adolescence. Clinical Endocrinology 1997; 46:727-733 Gill MS, Whatmore AJ, Tillman V, White A, Addison GM, Price DA, Clayton PE. Urinary IGF and IGF binding protein-3 in children with disordered growth. Clinical Endocrinology 1997; 46:483-492 Tillmann V, Buckler JMH, Kibirige MS, Price DA, Shalet SM, Wales JKH, Addison MG, Gill MS, Whatmore AJ, Clayton PE. Biochemical tests in the diagnosis of childhood growth hormone deficiency. J Clin Endocrinol Metab 1997;82:531-535 Tillmann V, Adojaan B, Shor R, Price DA, Tuvemo T. Physical development in Estonian children with type I diabetes. Diabetic Medicine 1996; 13: 97-101 Tillmann V, Price DA, Bucknall JL, Clayton PE. Experience within the Manchester Growth Clinic of growth hormone treatment of girls with Turner syndrome. In Albertsson-Wikland K, Ranke M (ed) Turner Syndrome in a Life-Span Perspective (proceedings of the international meeting). Elsevier Science B.V. 1995, 149-154 |
last updated: 06.10.2005
[ sulge aken ]